Difference between revisions of "Programmed death-ligand 1"

From Libre Pathology
Jump to navigation Jump to search
 
(31 intermediate revisions by 3 users not shown)
Line 1: Line 1:
'''Programmed death-ligand 1''', commonly abbreviated '''PD-L1''', is protein with an important role in immune system regulation, and thus [[cancer]] aggressiveness.
[[Image:PD-L1_positive_lung_adenocarcinoma_--_intermed_mag.jpg|right|thumb|[[Micrograph]] showing a PD-L1 positive non-small cell lung carcinoma (NSCLC). PD-L1 [[immunostain]] (22C3). (WC)]]
'''Programmed death-ligand 1''', commonly abbreviated '''PD-L1''', is a protein with an important role in immune system regulation and [[cancer]].  
[[Image:PD-L1 negative lung adenocarcinoma -- high mag.jpg|right|thumb|[[Micrograph]] showing a PD-L1 negative [[NSCLC]]. PD-L1 immunostain (22C3). (WC)]]


It is also known as '''CD274'''.<ref name=omim>{{OMIM|605402}}</ref>
Normally, PD-L1 on cells binds with [[programmed cell death 1]] on the T lymphocytes.<ref name=pmid22658126/>
 
PD-L1 is also known as '''CD274'''.<ref name=omim>{{OMIM|605402}}</ref>


==General==
==General==
*[[IHC]] testing using a PD-L1 antibody predicts response to anti-PD-L1 drugs.<ref name=pmid26970723/>
[[Image:PD-L1_positive_lung_adenocarcinoma_in_lymph_node_--_intermed_mag.jpg|thumb|right|PD-L1 positive lung adenocarcinoma in a lymph node. 22C3 PD-L1 immunostain. (WC)]]
*In theory, positive PD-L1 [[IHC|immunostaining]] predicts response to anti-PD-L1 drugs.<ref name=pmid26970723/>
**Carcinoma cell is  considered "PD-L1 positive" if the cell membrane is partially or completely stained.<ref name="pmid27389313">{{Cite journal  | last1 = Scheel | first1 = AH. | last2 = Dietel | first2 = M. | last3 = Heukamp | first3 = LC. | last4 = Jöhrens | first4 = K. | last5 = Kirchner | first5 = T. | last6 = Reu | first6 = S. | last7 = Rüschoff | first7 = J. | last8 = Schildhaus | first8 = HU. | last9 = Schirmacher | first9 = P. | title = Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas. | journal = Mod Pathol | volume = 29 | issue = 10 | pages = 1165-72 | month = Oct | year = 2016 | doi = 10.1038/modpathol.2016.117 | PMID = 27389313 }}</ref>
*It is, however, more complex than that. Some tumour types are invariably positive, e.g. classical Hodgkin lymphoma, so testing is unhelpful. In contrast, tumors such as malignant melanoma respond regardless of PD-L1 immunoexpression.
*The plethora of companion diagnostics developed for each PD-1/ PD-L1 inhibitor has created challenges, as these assays include different IHC antibody clones, staining protocols and platforms, scoring systems, and cutoffs for defining positivity.
**Nivolumab - 28-8 (Dako)
**Pembrolizumab - 22C3 (Dako)
**Aterolizumab -  SP142 (Ventana)
**Durvalumab -  SP263 (Ventana)
**Avelumab - 73-10 (Dako)
 
===Background===
Cytotoxic T cell function is regulated by receptor pairs found on the tumour and lymphocyte:<ref name=pmid22658126>{{Cite journal  | last1 = Ribas | first1 = A. | title = Tumor immunotherapy directed at PD-1. | journal = N Engl J Med | volume = 366 | issue = 26 | pages = 2517-9 | month = Jun | year = 2012 | doi = 10.1056/NEJMe1205943 | PMID = 22658126 }}</ref>
{| class="wikitable sortable"
! Function
! Tumour cell
! T cell
|-
| Antigen presentation
| MHC
| TCR
|-
| Signal inhibition
| PD-1
| [[PD-L1]] (CD274), PD-L2 (CD273)
|}
===Adequacy of PD-L1===
*100 cells or more.<ref name=pmid31097091>{{cite journal |authors=Wang H, Agulnik J, Kasymjanova G, Fiset PO, Camilleri-Broet S, Redpath M, Cohen V, Small D, Pepe C, Sakr L, Spatz A |title=The metastatic site does not influence PD-L1 expression in advanced non-small cell lung carcinoma |journal=Lung Cancer |volume=132 |issue= |pages=36–38 |date=June 2019 |pmid=31097091 |doi=10.1016/j.lungcan.2019.04.009 |url=}}</ref>


==Prognosis==
==Prognosis==
*Good prognosis - in high-grade [[ovarian serous carcinoma]], associated with [[tumour-infiltrating lymphocytes]].<ref name=pmid26972336>{{Cite journal  | last1 = Webb | first1 = JR. | last2 = Milne | first2 = K. | last3 = Kroeger | first3 = DR. | last4 = Nelson | first4 = BH. | title = PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer. | journal = Gynecol Oncol | volume = 141 | issue = 2 | pages = 293-302 | month = May | year = 2016 | doi = 10.1016/j.ygyno.2016.03.008 | PMID = 26972336 }}</ref>
*Good prognosis - in high-grade [[ovarian serous carcinoma]], associated with [[tumour-infiltrating lymphocytes]].<ref name=pmid26972336>{{Cite journal  | last1 = Webb | first1 = JR. | last2 = Milne | first2 = K. | last3 = Kroeger | first3 = DR. | last4 = Nelson | first4 = BH. | title = PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer. | journal = Gynecol Oncol | volume = 141 | issue = 2 | pages = 293-302 | month = May | year = 2016 | doi = 10.1016/j.ygyno.2016.03.008 | PMID = 26972336 }}</ref>


==Drugs==
==Drugs - Immune checkpoint inhibitors==
*Atezolizumab.<ref name=pmid26970723>{{Cite journal  | last1 = Fehrenbacher | first1 = L. | last2 = Spira | first2 = A. | last3 = Ballinger | first3 = M. | last4 = Kowanetz | first4 = M. | last5 = Vansteenkiste | first5 = J. | last6 = Mazieres | first6 = J. | last7 = Park | first7 = K. | last8 = Smith | first8 = D. | last9 = Artal-Cortes | first9 = A. | title = Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. | journal = Lancet | volume =  | issue =  | pages =  | month = Mar | year = 2016 | doi = 10.1016/S0140-6736(16)00587-0 | PMID = 26970723 }}</ref>
*PD-1 inhibitors:
**Nivolumab (''Opdivo'', Bristol-Myers Squibb).
**Pembrolizumab (''Keytruda'', Merck).
 
*PD-L1 inhibitors:
**Atezolizumab (''Tecentriq'', Roche).<ref name=pmid26970723>{{Cite journal  | last1 = Fehrenbacher | first1 = L. | last2 = Spira | first2 = A. | last3 = Ballinger | first3 = M. | last4 = Kowanetz | first4 = M. | last5 = Vansteenkiste | first5 = J. | last6 = Mazieres | first6 = J. | last7 = Park | first7 = K. | last8 = Smith | first8 = D. | last9 = Artal-Cortes | first9 = A. | title = Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. | journal = Lancet | volume =  | issue =  | pages =  | month = Mar | year = 2016 | doi = 10.1016/S0140-6736(16)00587-0 | PMID = 26970723 }}</ref>
**Durvalumab (''Imfinzi'', AstraZeneca).
**Avelumab (''Bavencio'', Merck/Pfizer).


==Application of PD-L1 drugs==
===Anti-PD-L1 drugs - use===
PD-L1 antibodies are being used to treat:<ref name=pmid26895815>{{Cite journal  | last1 = Gandini | first1 = S. | last2 = Massi | first2 = D. | last3 = Mandalà | first3 = M. | title = PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis. | journal = Crit Rev Oncol Hematol | volume = 100 | issue =  | pages = 88-98 | month = Apr | year = 2016 | doi = 10.1016/j.critrevonc.2016.02.001 | PMID = 26895815 }}</ref>
PD-L1 antibodies are being used to treat:<ref name=pmid26895815>{{Cite journal  | last1 = Gandini | first1 = S. | last2 = Massi | first2 = D. | last3 = Mandalà | first3 = M. | title = PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis. | journal = Crit Rev Oncol Hematol | volume = 100 | issue =  | pages = 88-98 | month = Apr | year = 2016 | doi = 10.1016/j.critrevonc.2016.02.001 | PMID = 26895815 }}</ref>
*[[Malignant melanoma]].
*[[Malignant melanoma]].
Line 18: Line 56:
**Associated with response predicted by [[tumour-infiltrating lymphocytes]] and ''PD-L1 IHC'' positivity of the tumour cells.<ref name=pmid26970723/>
**Associated with response predicted by [[tumour-infiltrating lymphocytes]] and ''PD-L1 IHC'' positivity of the tumour cells.<ref name=pmid26970723/>
*[[Renal cell carcinoma]].
*[[Renal cell carcinoma]].
*[[Urothelial carcinoma]].
*[[Merkel cell carcinoma]]
*[[Acute myeloid leukemia]]


==See also==
==See also==
*[[Molecular pathology]].
*[[Molecular pathology]].
*[[Cytotoxic T-lymphocyte-associate antigen 4]].


==References==
==References==

Latest revision as of 19:59, 22 August 2024

Micrograph showing a PD-L1 positive non-small cell lung carcinoma (NSCLC). PD-L1 immunostain (22C3). (WC)

Programmed death-ligand 1, commonly abbreviated PD-L1, is a protein with an important role in immune system regulation and cancer.

Micrograph showing a PD-L1 negative NSCLC. PD-L1 immunostain (22C3). (WC)

Normally, PD-L1 on cells binds with programmed cell death 1 on the T lymphocytes.[1]

PD-L1 is also known as CD274.[2]

General

PD-L1 positive lung adenocarcinoma in a lymph node. 22C3 PD-L1 immunostain. (WC)
  • In theory, positive PD-L1 immunostaining predicts response to anti-PD-L1 drugs.[3]
    • Carcinoma cell is considered "PD-L1 positive" if the cell membrane is partially or completely stained.[4]
  • It is, however, more complex than that. Some tumour types are invariably positive, e.g. classical Hodgkin lymphoma, so testing is unhelpful. In contrast, tumors such as malignant melanoma respond regardless of PD-L1 immunoexpression.
  • The plethora of companion diagnostics developed for each PD-1/ PD-L1 inhibitor has created challenges, as these assays include different IHC antibody clones, staining protocols and platforms, scoring systems, and cutoffs for defining positivity.
    • Nivolumab - 28-8 (Dako)
    • Pembrolizumab - 22C3 (Dako)
    • Aterolizumab - SP142 (Ventana)
    • Durvalumab - SP263 (Ventana)
    • Avelumab - 73-10 (Dako)

Background

Cytotoxic T cell function is regulated by receptor pairs found on the tumour and lymphocyte:[1]

Function Tumour cell T cell
Antigen presentation MHC TCR
Signal inhibition PD-1 PD-L1 (CD274), PD-L2 (CD273)

Adequacy of PD-L1

  • 100 cells or more.[5]

Prognosis

Drugs - Immune checkpoint inhibitors

  • PD-1 inhibitors:
    • Nivolumab (Opdivo, Bristol-Myers Squibb).
    • Pembrolizumab (Keytruda, Merck).
  • PD-L1 inhibitors:
    • Atezolizumab (Tecentriq, Roche).[3]
    • Durvalumab (Imfinzi, AstraZeneca).
    • Avelumab (Bavencio, Merck/Pfizer).

Anti-PD-L1 drugs - use

PD-L1 antibodies are being used to treat:[7]

See also

References

  1. ↑ 1.0 1.1 Ribas, A. (Jun 2012). "Tumor immunotherapy directed at PD-1.". N Engl J Med 366 (26): 2517-9. doi:10.1056/NEJMe1205943. PMID 22658126.
  2. ↑ Online 'Mendelian Inheritance in Man' (OMIM) 605402
  3. ↑ 3.0 3.1 3.2 Fehrenbacher, L.; Spira, A.; Ballinger, M.; Kowanetz, M.; Vansteenkiste, J.; Mazieres, J.; Park, K.; Smith, D. et al. (Mar 2016). "Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.". Lancet. doi:10.1016/S0140-6736(16)00587-0. PMID 26970723.
  4. ↑ Scheel, AH.; Dietel, M.; Heukamp, LC.; Jöhrens, K.; Kirchner, T.; Reu, S.; Rüschoff, J.; Schildhaus, HU. et al. (Oct 2016). "Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas.". Mod Pathol 29 (10): 1165-72. doi:10.1038/modpathol.2016.117. PMID 27389313.
  5. ↑ Wang H, Agulnik J, Kasymjanova G, Fiset PO, Camilleri-Broet S, Redpath M, Cohen V, Small D, Pepe C, Sakr L, Spatz A (June 2019). "The metastatic site does not influence PD-L1 expression in advanced non-small cell lung carcinoma". Lung Cancer 132: 36–38. doi:10.1016/j.lungcan.2019.04.009. PMID 31097091.
  6. ↑ Webb, JR.; Milne, K.; Kroeger, DR.; Nelson, BH. (May 2016). "PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer.". Gynecol Oncol 141 (2): 293-302. doi:10.1016/j.ygyno.2016.03.008. PMID 26972336.
  7. ↑ Gandini, S.; Massi, D.; Mandalà, M. (Apr 2016). "PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis.". Crit Rev Oncol Hematol 100: 88-98. doi:10.1016/j.critrevonc.2016.02.001. PMID 26895815.
Retrieved from "https://librepathology.org/w/index.php?title=Programmed_death-ligand_1&oldid=53164"